letter dated July 31, 2023 intimating the record date for dividend

of Rs. 5/- (Rupees Five only) per equity share of Re. 1 each for the year ended March 31,

2023 recommended by the Board of Directors, we would like to confirm that the dividend

is subject to approval of the shareholders at the ensuing AGM. The dividend, if approved

by the shareholders at the ensuing AGM, will be paid/ dispatched on or before

September 29, 2023.

We request you to take the above on record.

Thanking you,

Yours faithfully,

For Jubilant Pharmova Limited

Naresh Kapoor

Company Secretary

Encl: as above

Naresh

Kapoor

Digitally signed

by Naresh Kapoor

Date: 2023.08.08

21:00:11 +05'30':

Letter by clicking on “Upload

Board

Resolution

/

Authority: Letter”

displayed

under “e-Voting” tab in your login or send scanned copy (PDF/

JPG Format) of the relevant Board Resolution/ Authority letter,

etc. with attested specimen signature of the duly authorised

signatory(ies) who are authorised to vote, to the Scrutiniser by

e-mail to CS rsbhatiacs@aol.com or investors@jubl.com with a

copy marked to evoting@nsdl. co.in.

2.

It is strongly recommended not to share your password with

any other person and take utmost care to keep your password

letter of appointment of Mr. Arun Seth as an

Independent Director setting out the terms and conditions

of his appointment including remuneration is available for

inspection electronically without any fee by members from

the date of circulation of this Notice up to the date of AGM

and during the AGM. Members can inspect the same at

www.jubilantpharmova.com.

Mr. Arun Seth, the proposed appointee, may be deemed to

be concerned or interested. None of the other Directors, Key

Managerial Personnel of the Company or their relatives is concerned

or interested, financially or otherwise, in the resolution set out

at Item No. 6 of the Notice. The Board of Directors recommends

the resolution set out at Item No. 6 of the Notice for approval of

members by way of Special Resolution.

ANNEXURE-A

Information pursuant to Regulation 36 of the SEBI (Listing

Obligations and Disclosure Requirements) Regulations, 2015

read with the provisions of the Secretarial Standard on General

Meetings issued by the Institute of Company Secretaries of

India regarding the Directors proposed to be appointed/re-

appointed

1.

Mr. Shyam S. Bhartia

Mr. Shyam S. Bhartia, aged 70 years, holds a bachelors’ degree

in commerce from St. Xavier’s College, Calcutta University, and

is a qualified cost and works accountant and a fellow member

of the Institute of Cost and Works Accountants of India (ICWAI).

He has been associated with various institutions and has served

as a Member of the Board of Governors, Indian Institute of

Technology (IIT), Mumbai and Indian Institute of Management

(IIM), Ahmedabad. He has also served as a Member of the

Executive Committee of the Federation of Indian Chamber

of Commerce & Industry (FICCI) & Confederation of Indian

Industry (CII) and was also a member of the Task Force on

Chemicals appointed by the Government of India. Mr. Shyam

S. Bhartia is a regular participant at the World Economic Forum

Annual Meeting in Davos. He is also a member of Governors

for Chemistry and Advanced Materials of the World Economic

Forum.

He is on the Board of the Company since June 21, 1978 and

holds 5,000 shares of the Company. He holds directorships in

the following companies/bodies corporate:

•

Jubilant Pharmova Limited (Listed Company)

•

Jubilant Ingrevia Limited (Listed Company)

•

Chambal Fertilisers and Chemicals Limited (Listed

Company)

•

Jubilant FoodWorks Limited (Listed Company)

•

Jubilant Capital Private Limited

•

SPB Trustee Company Private Limited

•

SSP Trustee Company Private Limited

•

SS Trustee Company Private Limited

•

SBS Trustee Company Private Limited

•

SBSSB Realty Trustee Co. Private Limited

•

SSBSB Realty Trustee Co. Private Limited

•

Jubilant Enpro Private Limited

•

SSBPB Investment Holding Private Limited

•

HSSS Investment Holding Private Limited:

Managing Director of the Company, being his brother. Mr.

Priyavrat Bhartia, Director, is son of Mr. Shyam S. Bhartia. He is

not related to any other Director or Key Managerial Personnel

of the Company. He has opted not to take any commission

or sitting fees from the Company during the Financial Year

2022-23.

Mr. Shyam S. Bhartia has confirmed that he is not debarred or

disqualified from being appointed or continuing as Director

of the Company by the SEBI, MCA, or any such other Statutory

Authority.

2. Mr. Hari S. Bhartia

Mr. Hari S. Bhartia, aged 67 years, is a Chemical Engineering

Graduate from the Indian Institute of Technology (IIT), Delhi,

he was conferred the Distinguished Alumni award by his alma

mater in 2000. He has been associated in various capacities

with the IIT and with the Ministry of Human Resource

Development, Government of India.

Mr. Hari S. Bhartia has rich experience in Industry and Trade

of four decades in multiple sectors and has been instrumental

in developing strategic alliances and affiliations with leading

global companies. He has over 38 years of experience in the

pharmaceuticals, life science and food service industries. He is

one of the promoters of the Company and is a guiding force to

the growth of the Company.

He is a former President of the Confederation of Indian Industry

(CII) (2010-2011) and a member of several educational,

scientific and technological programs of the Government

of India. He is a former Chairman of the Board of Governors

of the Indian Institute of Management (IIM), Raipur & Indian

Institute of Technology (IIT), Kanpur. He is currently a Member

of the International Advisory Board of McGill University,

Canada; Chairman of Board of Governors, Indian Institute of

Management, Visakhapatnam and Chairman of CII-Jubilant

Food & Agriculture Centre of Excellence.

Mr. Hari S. Bhartia is a member of several CEO Forums &

prominent being India-USA CEO Forum and India-France

CEO Forum. He is a regular participant at the World Economic

Forum Annual Meeting in Davos and is a member of the World

Economic Forum’s International Business Council; Community

of Chairpersons; Global Health and Healthcare Governors

Community; Family Business Community. He was the Co-Chair

of the Davos Annual Meeting of the World Economic Forum in

2015. He is also a Founding Member of Centre for Social and

Economic Progress (CSEP).

Mr. Hari S. Bhartia is a strong proponent of Corporate

Social Responsibility. He, along with Mr. Shyam S. Bhartia,

established Jubilant Bhartia Foundation, whose efforts are

directed towards community development with focus on

Primary Education, Basic Healthcare services and Livelihood

generation programs. He is also deeply involved in ‘Social

Entrepreneur of the Year Award - India’, a joint initiative of

Jubilant Bhartia Foundation and Schwab Foundation for Social

Entrepreneurship, with an objective of recognising promising

and successful social entrepreneurs in India.

His immense contributions have been recognised by various

awards. He, along with his brother, was felicitated with the:

Managing Director*

Arjun Shanker Bhartia

Joint: Managing

Managing Director

26 years of industry experience

Arjun Shanker Bhartia

Joint: Managing

Letter to the Roorkee facility. In October

2019, the USFDA again conducted an inspection of the

Roorkee facility and issued a Form 483 with six observations.

In March 2021, the USFDA conducted another inspection

of the Roorkee facility and issued a Form 483 with seven

observations. Subsequently in July 2021, USFDA listed the

Roorkee facility under import alert with an exception for

4 products manufactured at the facility. Subsequently,

exception for 3 out of 4 products has been withdrawn. In July

2022, the USFDA conducted another inspection at Roorkee

site and concluded with inspection classification as “OAI”

(Official Action Initiated) in October 2022.

The Company had engaged independent third party cGMP

consultants to mitigate the gaps identified by the USFDA and

has kept the USFDA updated on its corrective and preventive

actions. The Company continues to manufacture and supply

the products to all the other markets where the products

are approved, other than US. New product approvals for US

market with Roorkee plant as manufacturing site will get

withheld till the alleviation of the import alert. The Company

is committed to implement the necessary corrective actions

required to address the USFDA concerns at the earliest and it

continues to work in close coordination with the US agency.

During the FY 2022-23, JGL recalibrated its R&D strategy

to continually deliver innovative, high quality products for

various markets. The new strategy leverages variety of product

opportunities through in-licensing and/or external product

development in collaboration with specialised CROs. This is

expected to accelerate product introduction as well as deliver

the products in cost-effective manner. Further, JGL evaluated

all existing products under development and prioritised them

on the basis of technical and financial feasibility.

During the year, the Hon’ble National Company Law Tribunal,

Allahabad Bench pronounced its Order dated June 13,

2022 approving the scheme of arrangement between JGL

and the Company for Demerger of Active Pharmaceuticals

Ingredients (“API”) undertaking/business of JGL and vesting of

the same with the Company on a going concern basis with an

Appointed Date of April 1, 2022.

Total income of JGL during the Financial Year 2022-23 was

C3,266.22 million as compared to C6,812.29 million during

the Financial Year 2022-23 for the continuing operations post

demerger of API business.

The Company is in compliance with Regulation 24A of the

Listing Regulations. Secretarial Audit was conducted for JGL,

an unlisted material subsidiary of the Company. Copy of the

Secretarial Audit Report is attached as Annexure-1 to this

report. The Secretarial Report of JGL does not contain any

qualification, reservation or adverse comments or disclaimer.

Jubilant Cadista Pharmaceuticals Inc.

Jubilant Cadista Pharmaceuticals Inc., (‘Jubilant Cadista’) a

corporation incorporated in Delaware, US is a wholly-owned

subsidiary of Jubilant Pharma Holdings Inc. This company is

engaged in the business of developing, manufacturing and

marketing of solid dosage forms of generic prescription

pharmaceuticals at its US FDA approved manufacturing facility

in Salisbury, Maryland, US. Jubilant Cadista is also marketing

the solid dosage forms manufactured at Roorkee Plant, India

or other CMOs. Its customer base includes large wholesalers,

retail and pharmacy chains. As on March 31, 2023, there were

17 products marketed in the US with focus in the therapeutic

areas of CVS, CNS, Anti Allergic, Steroids, etc. Jubilant Cadista

also acts as CMO for 2 products marketed in US. Total income

of the company during the Financial Year 2022-23 was

C5,079.91 million as compared to C6,462.09 million during the

Financial Year 2021-22. The US FDA inspected the site last in

February 2020 that resulted in a rating of GMP compliance.

At our Salisbury, Maryland manufacturing facilities, structured

improvement projects have been undertaken that have

delivered significant conversion cost savings, while at the

same time improving safety rate, deviation rate, productivity,

batch rejections and service level.

Jubilant HollisterStier LLC

Jubilant HollisterStier LLC (‘JHS’) is a wholly-owned subsidiary

of Jubilant Pharma Holdings Inc. This subsidiary is a fully

integrated leading CMO player based out of North America

with operations in Spokane, Washington (USA) and Montreal,

(Canada). The facilities offer manufacturing services including

sterile injectable (both liquid and lyophilization), ampoules

and ophthalmic offerings from the Montreal site (ointments,

liquids and creams). This company is among the leading

Contract Manufacturers in North America for sterile injectable

and expanding its reach as a full scale ophthalmic solution

provider in the form of bottles including preservative free

ointments, liquids, creams and injectables. Its facilities are

approved by regulators across the world including US FDA,

Health Canada, ANVISA Brazil, PMDA Japan, Russia, MHRA and

various others. The products manufactured at both sites are

sold in over 50 countries across the globe by its customers.

The company lays strong emphasis on compliance and

protecting Intellectual Property Rights (IPR) for its customer

Corporate Overview | Statutory Reports | Financial Statements

51:

Managing Director apart from

ten (10) Non-Executive Directors, out of whom seven (7) are

Independent Directors including one (1) Woman Independent

Director and three (3) Non-Executive Non-Independent

Directors. The composition of the Board is in conformity with

Regulation 17 of the Listing Regulations and the relevant

provisions of the Act.

In accordance with the provisions of the Companies Act, 2013

and Articles of Association of the Company, Mr. Hari S. Bhartia

(DIN: 00010499) and Mr. Shyam S. Bhartia (DIN: 00010484)

retire by rotation at the ensuing AGM and being eligible, offer

themselves for re-appointment.

Mr. Pramod Yadav resigned from the Board with effect from

July 1, 2022. The Board places on record its appreciation for

the contributions made by him during his association with

the Board.

The Board in its meeting held on July 01, 2022 had appointed

Mr. Ramamurthi Kumar (DIN: 09139426) as an Additional

Director and further designated him as a Whole-time director

for a period of three (3) years. The shareholders have, at the

44th AGM of the Company held on September 26, 2022,

approved the appointment of Mr. Ramamurthi Kumar (DIN:

09139426) as Director and also as a Whole-time Director for a

period of three (3) years effective from July 1, 2022.

The tenure of Mr. Arun Seth (DIN 00204434) as a Non-

Executive Independent Director shall end on October 21,

2023. The Board has, at its meeting held on May 29, 2023,

based on recommendation of Nomination, Remuneration

& Compensation Committee has recommended the re-

appointment of Mr. Arun Seth as Independent Director for

another term of five (5) years upto October 21, 2028.

Mr. Shirish G. Belapure (DIN 02219458) has been appointed as

a Non-Executive Independent Director for a period of 5 years

effective from March 7, 2023. In the opinion of the Board,

Mr. Shirish G. Belapure is a person of integrity and fulfils the

conditions specified under the Act read with Rules thereunder

and the Listing Regulations for his appointment as an

Independent Director of the Company. In terms of Regulation

17(1C) of Listing Regulations, the said appointment has been

duly approved by the shareholders of the Company by way

of special resolution passed through postal ballot, result of

which was declared on April 13, 2023.

15. CHANGES IN KEY MANAGERIAL PERSONNEL

Mr. Rajiv Shah superannuated from the position of Company

Secretary and Compliance Officer from the close of business

hours of July 31, 2022.

Mr. Naresh Kapoor has been appointed as Company Secretary

and Compliance Officer of the Company effective from

August 1, 2022 and officiates as the Secretary to various Board

Committees.

Apart from above-mentioned changes, there is no other

change in Key Managerial Personnel of the Company during

the year.

16. MEETINGS OF THE BOARD

During the year under review, Five (5) meetings of the

Board of Directors of the Company were held on

May 27, 2022, July 1, 2022, August 2, 2022, October 21, 2022

and February 3, 2023.

For details of meetings of the Board and attendance of the

Directors, please refer to the Corporate Governance Report,

which forms part of this report.

17. COMPOSITION OF AUDIT COMMITTEE

The Audit Committee comprises the following Chairperson/

Member(s) as on March 31, 2023:

S. No.

Name

Category

1.

Mr. S. Sridhar, Chairperson

Non-Executive

Independent Director

2.

Ms. Sudha Pillai, Member

Non-Executive

Independent Director

3.

Dr. Ashok Misra, Member

Non-Executive

Independent Director

4.

Mr. Vivek Mehra, Member

Non-Executive

Independent Director

5.

Mr. Priyavrat Bhartia,

Member

Non-Executive Promoter

6.

Mr. Arvind Chokhany,

Member

Executive Non-

Independent Director

Further details on Audit Committee, including the meetings

and attendance of the members, terms of reference etc.,

please refer to the Corporate Governance Report, which forms

part of this report.

18. DECLARATION BY INDEPENDENT DIRECTORS

All Independent Directors have given declaration that they

meet the criteria of independence as provided under Section

149 of the Act and Regulation 16 of the Listing Regulations.

19. APPOINTMENT AND REMUNERATION POLICY

The

Company

has

implemented

Appointment

and

Remuneration Policy pursuant to the provisions of Section 178

of the Act and Regulation 19 read with Part D of Schedule II to

the Listing Regulations. Salient features of the Policy and other

details have been disclosed in the Corporate Governance

Report attached to this Report. The Policy is available at the

web-link: www.jubilantpharmova.com/investors/corporate-

governance/policies-and-codes/appointment-and-

remuneration-policy.

20. ANNUAL PERFORMANCE EVALUATION OF THE

BOARD

Pursuant to the provisions of the Act, the Listing Regulations

and the Performance Evaluation Policy of the Company, the

Board has carried out annual evaluation of its performance, its

committees, Chairperson and Directors through a structured

questionnaire process.

Performance of the Board was evaluated by each Director on

the parameters such as its role and responsibilities, business

Corporate Overview | Statutory Reports | Financial Statements

55:

Managing Director nor the Whole-time

Director(s) of the Company received any remuneration

or commission from any of its subsidiaries.

30. CORPORATE GOVERNANCE

As a responsible corporate citizen, the Company is committed

to maintain the highest standards of Corporate Governance

and believes in adhering the best corporate practices

prevalent globally.

A detailed Report on Corporate Governance is attached as

Annexure-6 and forms part of this Report. A certificate from

Mr. R. S. Bhatia, Practising Company Secretary (C.P. No. 2514),

Confirming Compliance with the conditions of Corporate

Governance, as stipulated in Clause E of Schedule V to the

Listing Regulations is attached to the Corporate Governance

Report.

The Board Members and Senior Management Personnel have

affirmed compliance with the Code of Conduct for Directors

and Senior Management for the year ended March 31, 2023.

A certificate from the Co-Chairman &: Managing Director

confirming the same is attached to the Corporate Governance

Report.

A certificate from the CEO and CFO confirming correctness

of the financial statements, adequacy of internal control

measures, etc. is also attached to the Corporate Governance

Report.

31. MANAGEMENT

DISCUSSION

AND

ANALYSIS

REPORT

The Management Discussion and Analysis Report on the

operations of the Company as provided under the Listing

Regulations has been given separately and forms part of this

Report.

32. ACKNOWLEDGEMENTS

Your Directors acknowledge with gratitude the co-operation

and assistance received from the Central and State Government

authorities. Your Directors thank the shareholders, debenture

holders, financial institutions, banks/ other lenders, debenture

trustee, customers, vendors and other business associates for

their confidence in the Company and its management and

look forward to their continued support. The Board wishes

to place on record its appreciation for the dedication and

commitment of the Company’s employees at all levels, which

has continued to be our major strength. We look forward to

their continued support in the future.

For and on behalf of the Board

Shyam S. Bhartia

Hari S. Bhartia

Managing Director

(1.45)

160.5:1

3

Mr. S. Sridhar,

Non-Executive Independent Director

(2.58)

2.53:1

4

Ms. Sudha Pillai,

Non-Executive Independent Director

(6.94)

2.69:1

5

Dr. Ashok Misra,

Non-Executive Independent Director

(6.79)

2.30:1

6

Mr. Sushil Kumar Roongta,

Non-Executive Independent Director

(5.38)

2.36:1

7

Mr. Vivek Mehra,

Non-Executive Independent Director

(7.50)

2.48:1

8

Mr. Arun Seth,

Non-Executive Independent Director

(8.30)

1.85:1

9

Mr. Shirish G. Belapure #6

Non-Executive Independent Director

Not Applicable

Not Applicable

10

Mr. Priyavrat Bhartia,

Non-Executive Director

-

-

11

Mr. Arjun Shanker Bhartia,

Non-Executive Director

-

-

12

Mr. Pramod Yadav, #4

Non-Executive Director

-

-

13

Mr. Arvind Chokhany,

Group CFO and Whole-time Director

8.13

71.56:1

14

Mr. Ramamurthi Kumar #5

Whole-time Director

Not Applicable

21.93:1

15

Mr. Arun Kumar Sharma,

Chief Financial Officer

6.50

Not Applicable

16

Mr. Rajiv Shah, #7

Company Secretary

9.75

Not Applicable

17

Mr. Naresh Kapoor, #8

Company Secretary

Not Applicable

Not Applicable

Notes:

1. Mr. Shyam S. Bhartia, Chairman, Mr. Priyavrat Bhartia, Mr. Arjun Shanker Bhartia and Mr. Pramod Yadav, Non-Executive Directors

have opted not to take commission and sitting fees for the Financial Year 2022-23.

2. 1,034 permanent employees were on the rolls of the Company as on March 31, 2023. Median of Total Cost to Company (CTC)

on payable basis has been taken for all on-roll employees as on March 31, 2023. Median salary of all on-roll employees is

C7,46,680.

Corporate Overview | Statutory Reports | Financial Statements

67:

Managing Director

IIT Delhi

Chemical

Engineering

41

01-Jan-82

67

11,98,98,702

-

-

2

Arvind Chokhany

Group CFO - Jubilant

Bhartia Group

CA, ICWA

27

01-Apr-21

51

5,34,31,442

CFO

Tata Projects

Limited

3

Arun Kumar

Sharma

Head - Group Treasury &

CFO Pharmova

B.Sc. CA

34

27-Aug-03

57

2,39,07,320

GM-Finance

Escorts Ltd.

4

Praveen Kumar

Gupta

Sr Vice President & Head-

Direct Taxation

FCA, FCS, LLB

26

25-Jan-05

49

2,10,58,423

DGM Taxation

Ballarpur Industries

Limited

5

K V S Satish Kumar

Chief Sustainability

Officer

PGD, MTECH

26

29-Apr-21

46

1,67,32,952

Chief Sustainability

Officer

PI Industries

Limited

6

Ramamurthi

Kumar

President - Jubilant

Pharma & Head - API

Business

DIPL, ICWAI, MBA

37

03-Feb-14

59

1,63,76,020

Director

Management

Consultant

7

Tushar Gupta

Vice President -

Corporate Strategy

PGDM, MBBS

8

25-Oct-21

36

1,42,43,078

Principal

Boston Consulting

Group

8

Gayatri Taragi

Vice President & Head-

Compensation & Benefits

PGDM, MBA

20

08-Feb-18

47

1,28,42,988

GM-HR

Airtel

9

Jaishree Sharma

Senior Director & Head -

Talent Acquisition

BAT

22

17-May-21

47

1,06,59,402

Director Global TA

Pearson India

EducationService

10

Jinang Pratapbhai

Parekh

Vice President - Sales

(API)

MBA BSC

17

01-Dec-20

42

81,19,036

VP Business

Development

Ningbo Menovo

Pharmaceuticals

B. Employed for full year and in receipt of remuneration for the year which in aggregate was not less than D10,200,000 per annum (other than those mentioned in Para A above) – Nil

Corporate Overview | Statutory Reports | Financial Statements

69:

managing director or whole-time director and holds by himself or along with his spouse and dependent children, not less than two percent of the equity shares of the company.

6.

Remuneration comprises salary, allowances, perquisites/ taxable value of perquisites, etc. Remuneration of Mr. Hari S. Bhartia includes commission payable.

7.

Abbreviations: AVP - Assistant Vice President; CFO - Chief Financial Officer; CS – Company Secretary, DGM - Deputy General Manager; GM - General Manager; HR - Human Resources; VP -

Vice President.

# These employees ceased to be in employment of the Company during the year.

For Jubilant Pharmova Limited

Shyam S. Bhartia

Hari S. Bhartia

Chairman

Co-Chairman &: Managing

Managing Director

(DIN: 00010499)

Ashok Misra

Chairman - Sustainability & CSR Committee

(DIN: 00006051)

NA

[Person specified under clause (d) of

sub-section (1) of section 380 of the Act]

(Wherever applicable).

Corporate Overview | Statutory Reports | Financial Statements

73:

letter as well as in spirit.

Highlights of Jubilant’s Corporate Governance regime

are:

•

Appropriate mix of Executive and Non-Executive

Directors on the Board;

•

Constitution of several committees for focused attention

and proactive flow of information;

•

Emphasis on ethical business conduct by the Board,

management and employees;

•

Employees Stock Option Plans - to attract, reward and

retain key senior executives;

•

Active employee participation in place; two top

executives on the Board of Directors;

•

Our business operates within a highly regulated

environment and ensuring compliances play a vital role

in the development of all businesses. In order to address

this requirement, the Company has implemented cloud

based compliance management and reporting system

across key entities at North America and India locations.

Annexure 6

•

Online monitoring of internal controls on all operations

spanning more than 1,500 control assertions through a

specially designed software to institutionalise a quarterly

system of certification to enable CEO/CFO certification of

internal controls as per Regulation 17(8) of the Securities

and Exchange Board of India (Listing Obligations and

Disclosure Requirements) Regulations, 2015 (Listing

Regulations);

•

Robust Risk Management and Controls Mapping for each

of the businesses and for the Company as a whole;

•

Timely, transparent and regular disclosures;

•

Paperless meetings of Board and Committees;

•

Comprehensive Corporate Sustainability Management

System;

•

Established Code of Conduct for Directors and Senior

Management as also for other employees;

•

Robust Vigil Mechanism and Ombudsperson Process;

•

Detailed Policy on Disclosure of Material Events and

Information;

•

Code of Conduct for Prevention of Insider Trading;

•

Focus on hiring, retaining and nurturing best talent and to

promote a culture of excellence across the organisation.

Exhaustive HR policies cover succession planning, training

and development, employee grievance handling, etc.;

and

•

Regular communication with shareholders including

e-mailing of quarterly results and press releases just

after release to the Stock Exchanges, e-mailing of Annual

Reports and Corporate Sustainability Reports and

obtaining online feedback from the shareholders.

The Securities and Exchange Board of India (‘SEBI’) regulates

Corporate Governance practices and disclosure for the listed

companies through the Listing Regulations. Jubilant is in full

compliance with the Listing Regulations.

B) BOARD OF DIRECTORS

(i)

Composition

As on March 31, 2023, the Board strength is thirteen (13),

which comprises seven (7) Non-Executive Independent

Directors including one (1) Independent Woman Director,

three (3) Non-Executive Non Independent Directors, one

(1): Managing

Managing Director#1

Executive and Promoter

5

5

No

Mr. S. Sridhar (DIN: 00004272)

Director

Non-Executive Independent

5

5

Yes

Ms. Sudha Pillai (DIN: 02263950)

Director

Non-Executive Independent

5

5

Yes

Dr. Ashok Misra (DIN: 00006051)

Director

Non-Executive Independent

5

4

Yes

Mr. Sushil Kumar Roongta (DIN: 00309302)

Director

Non-Executive Independent

5

5

Yes

Mr. Vivek Mehra (DIN: 00101328)

Director

Non-Executive Independent

5

5

Yes

Mr. Arun Seth (DIN: 00204434)

Director#4

Non-Executive Independent

5

3

Yes

Mr. Shirish G. Belapure (DIN: 02219458)#5

Non-Executive Independent

Not applicable

Not applicable

Not applicable

Mr. Priyavrat Bhartia (DIN: 00020603)

Director

Non-Executive and Promoter

5

3

Yes

Mr. Arjun Shanker Bhartia (DIN: 03019690)

Director

Non-Executive and Promoter

5

5

No

Mr. Pramod Yadav (DIN: 05264757)

Director#2

Non-Executive Non-Independent

1

1

Not applicable

Mr. Arvind Chokhany (DIN: 06668147)

Group Chief Financial Officer and

Whole-time Director

Executive - Non Independent

5

5

Yes

Mr. Ramamurthi Kumar (DIN: 09139426)

Whole-time Director#3

Executive - Non Independent

4

4

Yes

Notes:

1.

Mr. Shyam S. Bhartia and Mr. Hari S. Bhartia are related to each other, being brothers. Further, Mr. Priyavrat Bhartia is son of Mr. Shyam S.

Bhartia and Mr. Arjun Shanker Bhartia is son of Mr. Hari S. Bhartia.

2.

Mr. Pramod Yadav ceased to be a Director effective from July 1, 2022.

3.

Mr. Ramamurthi Kumar has been appointed as Whole-time Director of the Company for a period of three (3) years effective from July 1,

2022. His appointment has been duly approved by the shareholders of the Company at the AGM held on September 26, 2022.

4.

The tenure of Mr. Arun Seth as Independent Director shall expire on October 21, 2023. The Board has, at its meeting held on May 29, 2023,

recommended re-appointment of Mr. Arun Seth as Independent Directors for another term of five (5) consecutive years upto October 21,

2028, subject to the approval of Shareholders by way of Special Resolution.

5.

Mr. Shirish G. Belapure has been appointed as Non-Executive Independent Director for a period of five (5) years effective from March 7,

2023. His appointment has been duly approved by the shareholders of the Company by way of Special Resolution passed through postal

ballot, results of which were declared on April 13, 2023.

Jubilant Pharmova Limited

Annual Report 2022-23

76:

Managing Director shall not serve as an Independent Director in more than three (3) listed entities.

Jubilant Pharmova Limited

Annual Report 2022-23

78:

Managing Director, Group

Chief Human Resources Officer and Head-Benefits

& Compensation are invitees to the NRC Committee

Meetings.

(iii) Meetings, Quorum and Attendance

The Committee met as frequently as circumstances

necessitate with atleast one meeting in a year. The

quorum for the meeting is two (2) members or one-third

(1/3) of members, whichever is greater including atleast

one Independent Director.

During the year, the Committee met three (3) times i.e.

on May 27, 2022, July 1, 2022 and August 1, 2022.

Attendance details of the members are given in the table

below:

Name of the Committee

Member

Meetings

Held During

Tenure

Meetings

Attended

Ms. Sudha Pillai, Chairperson

3

3

Mr. Shyam S. Bhartia, Member

3

3

Mr. Sushil Kumar Roongta,

Member

3

3

Mr. Vivek Mehra, Member

3

3

Corporate Overview | Statutory Reports | Financial Statements

83:

Managing Director and Whole-time Director(s) are contractual. Appointment of Whole-time Director is

terminable on 3 months’ notice or by payment of Basic Salary in lieu thereof. No severance fee is payable to: Managing

Managing Director, for

the Financial Year 2021-22.

2.

Re-appointment of Mr. Hari S. Bhartia as Co-Chairman and: Managing

Managing Director is enclosed as

Annexure-B. The Code of Conduct is posted on the

Company’s

website

https://www.jubilantpharmova.

com/investors/corporate-governance/policies-and-

codes/code-of-conduct

ii.

Code of Conduct for Prevention of Insider Trading

The Company has adopted a Code of Conduct for

Prevention of Insider Trading with a view to regulate

trading in securities of the Company by the Designated

Persons. The Code also includes requirements for the

Structured Digital Database, prescribed format for

reporting of trading in the securities of the Company,

reporting of violations to the stock exchanges etc.

The Company has also implemented the Policy and

Procedure for inquiry in case of leak or suspected leak

of Unpublished Price Sensitive Information (‘UPSI’),

pursuant to the SEBI Insider Trading Regulations.

Dealing in the shares of the Company by the Designated

Persons is effectively monitored for ensuring compliance

with the Code. Report on dealing in the shares of the

Company by the Designated Persons is placed before

the Chairperson of the Audit Committee and the Board

on a quarterly basis. Pursuant to the SEBI Insider Trading

Regulations, the Company has established a Structured

Digital Database with adequate internal controls and

checks such as time stamp and audit trails. The Company

has also established effective internal controls to ensure

compliance with the SEBI Insider Trading Regulations.

Corporate Overview | Statutory Reports | Financial Statements

91:

letter dated May 6, 2021.

3

Non-Convertible

Debentures

100.00

CRISIL Ratings

Limited

CRISIL AA

Positive

Rating outlook has been changed

to Positive from Rating watch with

developing

implications

and

has

simultaneously been withdrawn vide: letter dated May 6, 2021.

Jubilant Pharmova Limited

Annual Report 2022-23

100

Managing Director and Chief Financial Officer,

is enclosed as Annexure-D which, inter alia, certifies to

the Board about accuracy of the financial statements and

adequacy of internal controls for the financial reporting

purpose.

For and on behalf of the Board

Shyam S. Bhartia

Hari S. Bhartia

Chairman

Co-Chairman &: Managing

Managing Director

Annexure C

Certificate By Practicing Company Secretary on Compliance with the Conditions of Corporate Governance as per

Schedule V(E) of the SEBI (LODR) Regulations

To,

The Members of

Jubilant Pharmova Limited

CIN: L24116UP1978PLC004624

Bhartiagram, Gajraula

District Amroha – 244223,

Uttar Pradesh, India

1.

I have examined the compliance of the conditions of Corporate Governance by Jubilant Pharmova Limited (the ‘Company’) for the

Financial Year ended on March 31, 2023, as stipulated under Regulations 17 to 27, clauses (b) to (i) and (t) of sub regulation (2) of

Regulation 46 and para C, D and E of Schedule V of the Securities and Exchange Board of India (Listing Obligations and Disclosure

Requirements) Regulations, 2015.

2.

The compliance of the conditions of Corporate Governance is the responsibility of the management. My examination has been

limited to the review of the procedures and implementations thereof, adopted by the Company for ensuring the compliance of the

conditions of Corporate Governance. It is neither an audit nor an expression of opinion on the financial statements of the Company.

3.

In my opinion and to the best of our information and according to the explanations given to me and the representation made by the

directors and the management, I certify that the Company has complied with the mandatory conditions of Corporate Governance as

stipulated under the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

4.

I further state that such compliance is neither an assurance as to the future viability of the Company nor the efficiency or effectiveness

with which the management has conducted the affairs of the Company.

R. S. Bhatia

Practicing Company Secretary

C.P. No.: 2514

Date: May 29, 2023

Peer Review No. 1496/2021

Place: Delhi

UDIN: F002599E000403318

Corporate Overview | Statutory Reports | Financial Statements

103:

Managing Director

Date: May 29, 2023

Jubilant Pharmova Limited

Annual Report 2022-23

104:

Dear Stakeholders,

I am pleased to present Jubilant Pharmova Limited's BRSR Report for the fiscal year 2023 (FY2023).

As a pharmaceutical company, our core purpose is to improve lives through scientific and medical

advancements. Our commitment to harnessing the power of science and technology has been

instrumental in our holistic growth.

Within this report, we emphasise the sustainability challenges and opportunities encountered during

FY 2023. Despite the obstacles faced, our Company achieved stable revenues due to the diversification

of our businesses. We have expedited capacity expansions to bolster our capabilities and meet evolving

demands. Moreover, we have successfully reduced our absolute greenhouse gas (GHG) emissions year

after year. This year, we are also fulfilling the reporting requirements of the Business Responsibility and

Sustainability Reporting (BRSR) as mandated by SEBI.

Corporate Overview | Statutory Reports | Financial Statements

111:

Managing Director

DIN: 00010499

Arun Kumar Sharma

Chief Financial Officer

Naresh Kapoor

Company Secretary

Place: Noida

Date: 29 May 2023

Place: Noida

Date: 29 May 2023

Jubilant Pharmova Limited

Annual Report 2022-23

144:

Managing Director

DIN: 00010499

Arun Kumar Sharma

Chief Financial Officer

Naresh Kapoor

Company Secretary

Place: Noida

Place: Noida

Date: 29 May 2023

Date: 29 May 2023

(D in million)

Notes

For the year ended

31 March 2023

31 March 2022

Revenue from operations

20

8,101.17

7,257.34

Other income

21

1,378.92

1,261.58

Total income

9,480.09

8,518.92

Expenses

Cost of materials consumed

22

3,962.95

3,702.61

Purchases of stock-in-trade

23

148.05

26.28

Changes in inventories of finished goods and work-in-progress

24

34.54

(406.08)

Employee benefits expense

25

1,672.72

1,636.44

Finance costs

26

185.24

109.87

Depreciation and amortisation expense

27

432.50

369.12

Other expenses

28

2,250.65

2,233.47

Total expenses

8,686.65

7,671.71

Profit before tax

793.44

847.21

Tax expense

29

- Current tax

138.17

142.76

- Deferred tax charge/(credit)

156.44

(100.47)

Total tax expense

294.61

42.29

Profit for the year

498.83

804.92

Other comprehensive income

Items that will not be reclassified to profit or loss

Changes in fair value of equity investments which are classified at fair value

through other comprehensive income

20.89

(2.36)

Remeasurement of defined benefit obligations

(11.89)

12.42

Income tax relating to items that will not be reclassified to profit or loss

29

4.16

(4.31)

Other comprehensive income for the year, net of tax

13.16

5.75

Total comprehensive income for the year

511.99

810.67

Earnings per equity share of D 1 each

50

Basic (C)

3.13

5.05

Diluted (C)

3.13

5.05

Corporate Overview | Statutory Reports | Financial Statements

145:

Managing Director

DIN: 00010499

Arun Kumar Sharma

Chief Financial Officer

Naresh Kapoor

Company Secretary

Place: Noida

Place: Noida

Date: 29 May 2023

Date: 29 May 2023

Corporate Overview | Statutory Reports | Financial Statements

147:

Managing Director

DIN: 00010499

Arun Kumar Sharma

Chief Financial Officer

Naresh Kapoor

Company Secretary

Place: Noida

Place: Noida

Date: 29 May 2023

Date: 29 May 2023

Corporate Overview | Statutory Reports | Financial Statements

149:

letter, and in any event not earlier than 1 year from the grant date and

no later than a period of 5 years from the grant date. Vesting of Options is a function of achievement of performance criteria or any other

criteria, as specified by the Committee and communicated in the grant: letter

In 2008-09, Jubilant Employees Welfare Trust (‘Trust’) was constituted for the purpose of acquisition of equity shares of the Company from

the secondary market or subscription of shares from the Company, to hold the shares and to allocate/transfer these shares to eligible

employees of the Company/subsidiaries from time to time on the terms and conditions specified under Plan 2018.

Up to 31 March 2023, Jubilant Employees Welfare Trust (the “Trust”) purchased 211,325 equity shares of the Company from the open

market, out of which 1,868 equity shares were transferred to the employees on exercise of Options.

The movement in the number of equity shares held by trust:

As at

31 March 2023

31 March 2022

At the commencement of the year

107,140

107,140

Purchased during the year

104,185

-

Transferred to the employees on exercise of Options during the year

(1,868)

-

At the end of the year

209,457

107,140

The movement in the stock options under “Plan 2018” during the year is set out below:

For the year ended

31 March 2023

31 March 2022

Number of

options

Weighted average

exercise price (D)

Number of

options

Weighted average

exercise price (D)

Outstanding at the beginning of the year

35,734

355.61

-

-

Granted during the year

604,540

14.19

35,734

355.61

Forfeited/lapsed during the year

(7,071)

407.85

-

-

Exercised during the year

(1,868)

1.00

-

-

Outstanding at the end of the year

631,335

29.14

35,734

355.61

Exercisable at the end of the year

7,574

574.23

-

-

The weighted average share price during the year was C 363.87 per share.

Notes to the financial statements for the year ended 31 March 2023

Corporate Overview | Statutory Reports | Financial Statements

195

Managing Director

DIN: 00010499

Arun Kumar Sharma

Chief Financial Officer

Naresh Kapoor

Company Secretary

Place: Noida

Place: Noida

Date: 29 May 2023

Date: 29 May 2023

Notes to the financial statements for the year ended 31 March 2023

Jubilant Pharmova Limited

Annual Report 2022-23

198:

Managing Director

DIN: 00010499

Arun Kumar Sharma

Chief Financial Officer

Naresh Kapoor

Company Secretary

Place: Noida

Date: 29 May 2023

Place: Noida

Date: 29 May 2023

(D in million)

Notes

As at

31 March 2023

31 March 2022

EQUITY AND LIABILITIES

Equity

Equity share capital

14

159.09

159.19

Other equity

53,833.67

53,026.44

Equity attributable to owners of the Company

53,992.76

53,185.63

Non-controlling interest

(74.89)

(21.63)

Total equity

53,917.87

53,164.00

Liabilities

Non-current liabilities

Financial liabilities

i.

Borrowings

16(A)

31,103.62

24,642.42

ii.

Lease liabilities

2,132.83

2,121.93

iii.

Other financial liabilities

19

18.49

5.04

Provisions

17

922.48

956.66

Deferred tax liabilities (net)

8

3,062.08

3,029.65

Other non-current liabilities

20

2,685.08

72.96

Total non-current liabilities

39,924.58

30,828.66

Current liabilities

Financial liabilities

i.

Borrowings

16(B)

2,997.16

4,633.74

ii.

Lease liabilities

534.02

521.93

iii.

Trade payables

18

Total outstanding dues of micro enterprises and small enterprises

175.60

62.86

Total outstanding dues of creditors other than micro enterprises and

small enterprises

8,037.57

5,614.54

iv.

Other financial liabilities

19

3,354.54

2,350.85

Other current liabilities

20

1,217.82

1,518.64

Provisions

17

783.53

868.39

Current tax liabilities (net)

623.78

345.06

Total current liabilities

17,724.02

15,916.01

Total liabilities

57,648.60

46,744.67

Total equity and liabilities

111,566.47

99,908.67

Corporate Overview | Statutory Reports | Financial Statements

207:

Managing Director

DIN: 00010499

Arun Kumar Sharma

Chief Financial Officer

Naresh Kapoor

Company Secretary

Place: Noida

Date: 29 May 2023

Place: Noida

Date: 29 May 2023

Corporate Overview | Statutory Reports | Financial Statements

209:

Managing Director

DIN: 00010499

Arun Kumar Sharma

Chief Financial Officer

Naresh Kapoor

Company Secretary

Place: Noida

Place: Noida

Date: 29 May 2023

Date: 29 May 2023

Corporate Overview | Statutory Reports | Financial Statements

211:

Managing Director

DIN: 00010499

Arun Kumar Sharma

Chief Financial Officer

Naresh Kapoor

Company Secretary

Place: Noida

Place: Noida

Date: 29 May 2023

Date: 29 May 2023

(D in million)

For the year ended

31 March 2023

31 March 2022

D.

Effect of exchange rate changes

705.29

572.88

Net increase in cash and cash equivalents (A+B+C+D)

301.00

4,818.62

Add: cash and cash equivalents at the beginning of year

9,838.19

5,019.57

Cash and cash equivalents at the end of the year (Refer note 12(a))

10,139.19

9,838.19

# Refer note 16.4 for movement of liabilities arising from financing activities.

Note:

1. Consolidated Statement of Cash Flows has been prepared under the indirect method as set out in the Ind AS 7 “Statement of Cash

Flows”.

Corporate Overview | Statutory Reports | Financial Statements

213:

Managing Director

(CCMD) of the Group are responsible for allocating resources

and assessing performance of the operating segments, and

accordingly, identified as the chief operating decision maker.

Revenues, expenses, assets and liabilities, which are common

to the enterprise as a whole and are not allocable to segments

Notes to the consolidated financial statements for the year ended 31 March 2023

Corporate Overview | Statutory Reports | Financial Statements

225:

Managing Director of the Parent Company have been identified as the Chief Operating Decision Maker

(CODM) as defined by Ind AS 108 “Operating Segments”. Operating Segments have been defined and presented based on the regular

review by the CODM to assess the performance of each segment and to make decision about allocation of resources.

Pursuant to the changes during the current year in the structure of the Group’s internal organisation and the internal reporting to the

CODM, in a manner that causes the composition of reportable segments to change, the Group has reassessed its reportable segments in

accordance with Ind AS 108. The changes in reportable segments are as below:

•

Active Pharmaceutical Ingredients, earlier disclosed under “Pharmaceuticals”, is now disclosed along with Contract Research and

Development Services as “Contract Research, Development and Manufacturing Organisation’;

•

Contract Manufacturing Operations, earlier disclosed under “Pharmaceuticals”, is now disclosed separately and renamed as “Contract

Development and Manufacturing Organisation - Sterile Injectables”;

•

Allergy, earlier disclosed under “Pharmaceuticals”, is now disclosed separately and renamed as “Allergy Immunotherapy”; and

•

Radiopharma and Generics, earlier disclosed under “Pharmaceuticals”, are now disclosed separately.

Notes to the consolidated financial statements for the year ended 31 March 2023

Jubilant Pharmova Limited

Annual Report 2022-23

260:

letter, and in any event not earlier than 1 year from the grant date and

no later than a period of 5 years from the grant date. Vesting of Options is a function of achievement of performance criteria or any other

criteria, as specified by the Committee and communicated in the grant: letter

In 2008-09, Jubilant Employees Welfare Trust (‘Trust’) was constituted for the purpose of acquisition of equity shares of the Company from

the secondary market or subscription of shares from the Company, to hold the shares and to allocate/transfer these shares to eligible

employees of the Company/subsidiaries from time to time on the terms and conditions specified under Plan 2018.

Up to 31 March 2023, Jubilant Employees Welfare Trust (the “Trust”) purchased 211,325 equity shares of the Company from the open

market, out of which 1,868 equity shares were transferred to the employees on exercise of Options.

The movement in the number of equity shares held by trust:

(D in million)

As at

31 March 2023

31 March 2022

At the commencement of the year

107,140

107,140

Purchased during the year

104,185

-

Transferred to the employees on exercise of Options during the year

(1,868)

-

At the end of the year

209,457

107,140

The movement in the stock options under “Plan 2018” during the year is set out below:

For the year ended

31 March 2023

31 March 2022

Number of

options

Weighted

average exercise

price (D)

Number of

options

Weighted

average exercise

price (D)

Outstanding at the beginning of the year

35,734

355.61

-

-

Granted during the year

604,540

14.19

35,734

355.61

Forfeited/lapsed during the year

(7,071)

407.85

-

-

Exercised during the year

(1,868)

1.00

-

-

Outstanding at the end of the year

631,335

29.14

35,734

355.61

Exercisable at the end of the year

7,574

574.23

-

-

The weighted average share price during the year was C 363.87 per share.

Notes to the consolidated financial statements for the year ended 31 March 2023

Jubilant Pharmova Limited

Annual Report 2022-23

272

letter.

The movement in restricted stock awards under Plan 2020 during the year, is set out below:

For the year ended

For the year ended

31 March 2023

31 March 2022

No of awards

Exercise price

No of awards

Exercise price

Unvested at the beginning of the year

5,085

-

5,816

-

Granted during the year

-

-

917

-

Issued during the year

-

-

917

-

Cancelled during the year

350

-

-

-

Vested during the year

1,247

-

1,648

-

Unvested at the end of the year

3,488

-

5,085

-

Notes to the consolidated financial statements for the year ended 31 March 2023

Corporate Overview | Statutory Reports | Financial Statements

273:

Managing Director

DIN: 00010499

Arun Kumar Sharma

Chief Financial Officer

Naresh Kapoor

Company Secretary

Place: Noida

Date: 29 May 2023

Place: Noida

Date: 29 May 2023

Notes to the consolidated financial statements for the year ended 31 March 2023

Corporate Overview | Statutory Reports | Financial Statements

277:

Managing Director

DIN: 00010499

Jubilant Pharmova Limited

Annual Report 2022-23

280:

Managing Director

Mr. Priyavrat Bhartia*

Joint -: Managing

